Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jun 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-06-25

Reporting Person: BRADSHER NEAL C (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-25	Common Shares	M	24720	$2.20	Acquired	87628	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-25	OPTION TO PURCHASE COMMON SHARES	$2.20	M	24720	Disposed	2021-06-30	COMMON SHARES (24720)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	34005379	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
OPTION TO PURCHASE COMMON SHARES	$0.8263	2030-07-01	COMMON SHARES (40000)	40000	Direct
OPTION TO PURCHASE COMMON SHARES	$1.03	2029-06-30	COMMON SHARES (40000)	40000	Direct
OPTION TO PURCHASE COMMON SHARES	$1.67	2023-06-30	COMMON SHARES (49440)	49440	Direct
OPTION TO PURCHASE COMMON SHARES	$2.55	2022-06-30	COMMON SHARES (24720)	24720	Direct

Footnotes

F1: These securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be indirectly beneficially owned by: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher (the "Reporting Person"), as President of Broadwood Capital. Each of Broadwood Capital and the Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that Broadwood Capital or the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: These options are currently exercisable.